Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 34.25
Bid: 33.50
Ask: 35.00
Change: -0.50 (-1.44%)
Spread: 1.50 (4.478%)
Open: 34.75
High: 34.50
Low: 34.00
Prev. Close: 34.75
CREO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Positive NHS health economics data

3 Jun 2020 07:00

RNS Number : 7399O
Creo Medical Group PLC
03 June 2020
 

 

Creo Medical Group plc

("Creo" or the "Company")

 

Positive NHS health economics data

Savings of nearly £5,000 per procedure using Speedboat instead of traditional surgery

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces that initial data from the UK's leading user of the Company's Speedboat device demonstrates that the use of Speedboat can save NHS hospitals nearly £5,000 per procedure versus a traditional surgical outcome for patients. Health economic data analysed from a cohort of UK patient cases is estimated to have saved in excess of £400,000 of NHS funding in just one hospital.

 

The data demonstrates the health economic benefits for using the Company's CROMA Advanced Energy Platform with Speedboat, the first of Creo's suite of advanced energy devices designed for use in flexible endoscopy. Speedboat's advanced surgical procedures use endoscopy to remove gastrointestinal pre-cancerous lesions under sedation rather than a surgical outcome requiring general anaesthetic, hospital stay and a possible loss of organ function for the patient. The data validates both the intuitive savings one would expect as well as validating the analysis when Speedboat development first began.

 

The full data is expected to be published in October 2020 and the overall costs savings could be higher when the additional follow up costs associated with surgery is factored in. A further announcement will be made once the data is published in full.

 

Craig Gulliford, Chief Executive Officer of Creo, commented:

"We are pleased that the initial positive NHS health economics data further supports and validates the adoption of Speedboat procedures against the current standard of care, with the savings demonstrated being greater than were originally anticipated in our original i4i funding applications. The roll-out of our technology throughout the NHS, supported by our recently announced commercialisation agreement with the Department for Health, will empower endoscopists and surgeons to change the way they operate, bring significant benefits to their patients and releases funding for trusts to be deployed elsewhere."

 

Enquires:

 

Creo Medical Group plc

investors.creomedical.com

Richard Rees (CFO)

+44 (0)1291 606 005

 

 

Cenkos Securities plc

+44 (0)20 7397 8900

Stephen Keys / Cameron MacRitchie (NOMAD)

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com

Paul McManus / Lianne Cawthorne 

Mob: +44 (0)7980 541 893 / +44 (0)7515 909 238 

 

About Creo Medical 

 

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical Advanced Energy Platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions. 

 

The Company's strategy is to bring its CROMA Advanced Energy Platform powered by unique full spectrum adaptive technology to market enabling a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment. 

 

For more information about Creo Medical please see our website, investors.creomedical.com 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCKKBBPABKDNAK
Date   Source Headline
20th Mar 20244:52 pmRNSHolding(s) in Company
19th Mar 20247:00 amRNSWelsh Labour Leader visits Creo’s facilities
13th Mar 20243:05 pmRNSHolding(s) in Company
11th Mar 20242:00 pmRNSLTIP Awards
6th Mar 20244:35 pmRNSHolding(s) in Company
1st Mar 20247:00 amRNSMicrowave Lung Ablation Update
7th Feb 20249:12 amRNSTrading Update - Replacement
7th Feb 20247:00 amRNSTrading Update
5th Feb 20247:00 amRNSStrategic Collaboration with Khalifa University
31st Jan 20247:00 amRNSSpeedboat® UltraSlim roll-out reaches Asia Pacific
22nd Jan 20247:00 amRNSAward of Shares under Share Incentive Plan
10th Jan 20247:00 amRNSFirst use of Speedboat® UltraSlim in Latin America
15th Dec 20237:00 amRNSFirst use of Speedboat® UltraSlim in the USA
13th Dec 20237:00 amRNSFirst European Speedboat® UltraSlim procedure
7th Nov 20237:00 amRNSCapital Markets Day
1st Nov 20237:00 amRNSSpeedboat® UltraSlim: US FDA Clearance
25th Oct 20237:00 amRNSSB UltraSlim: EU launch accelerated by 18 months
16th Oct 202310:16 amRNSChange of Nominated Adviser and Joint Broker
12th Oct 20237:00 amRNSInvestor Presentation
12th Sep 20237:00 amRNSHalf-year Report
5th Sep 20237:00 amRNSNotice of Results
16th Aug 20237:00 amRNSRoyal Oldham SSD service update
3rd Aug 20237:00 amRNSHalf Year Trading Update
28th Jul 20237:00 amRNSTotal Voting Rights
24th Jul 202310:40 amRNSAward of Shares under Share Incentive Plan
6th Jul 202311:33 amRNSIssue of Equity and TVR
27th Jun 20231:15 pmRNSResult of AGM
27th Jun 20237:00 amRNSAGM Statement & Directorate Succession Planning
26th Jun 20237:00 amRNSFirst upper GI Speedboat procedure in Europe
22nd Jun 20237:00 amRNSAppointment of Marco Scarci
19th Jun 20237:00 amRNSSpeedboat Inject upper GI clearance in Europe
1st Jun 20237:00 amRNSSpeedboat™ Inject selected by NICE for assessment
26th May 20237:00 amRNSPosting of Annual Report and Notice of AGM
23rd May 20237:00 amRNSFirst in-human milestone for MicroBlate™ Flex
17th May 20237:00 amRNSRoyal Oldham Hospital Agreement
15th May 20237:00 amRNSAttendance at Digestive Disease Week
26th Apr 20237:00 amRNSFinal Results
14th Apr 20237:00 amRNSAlbyn Medical earn out update
31st Mar 202310:45 amRNSTotal Voting Rights
31st Mar 20237:00 amRNSMicroBlate™ Flex clinical study
13th Mar 20236:13 pmRNSDirector/PDMR and PCA Share Dealings
13th Mar 20237:00 amRNSHolding(s) in Company
8th Mar 202310:25 amRNSResult of GM
6th Mar 202311:05 amRNSSecond Price Monitoring Extn
6th Mar 202311:00 amRNSPrice Monitoring Extension
21st Feb 202310:29 amRNSHolding(s) in Company
17th Feb 20232:05 pmRNSSecond Price Monitoring Extn
17th Feb 20232:00 pmRNSPrice Monitoring Extension
17th Feb 202312:10 pmRNSLaunch of Open Offer and Posting of Circular
16th Feb 20236:04 pmRNSResult of Placing and Subscription

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.